Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

Exclusion Criteria

• •Patients who have uncontrolled respiratory disease (asthma, cystic fibrosis, etc.)
• •Patients who present with intercurrent disease active at the time of starting desensitization.
• •Non IgE mediated or non-immunological adverse reactions to milk or peanuts.
• •Malignant or immunopathological diseases and/or severe primary or secondary immune deficiencies.
• •Patients receiving oral immunosuppressor therapy.
• •Patients receiving β-blockers (including topical formulations), or who receive daily doses of NSAIDs, aspirin or ACE inhibitors for cardiac issues.
• •Associated diseases contraindicating the use of epinephrine: cardiovascular disease, severe hypertension or hypotension.
• •Patients diagnosed with eosinophilic gastrointestinal disorders, including patients with a history of antacid use for reflux related to food impaction or with a history of esophageal spasm.
• •Patients already tolerating processed/cooked forms of the food (e.g.,baked goods with milk).